NICE invites Roche to submit Tecentriq for CDF

3rd August 2017 Uncategorised 0

Roche’s Tecentriq has been rejected by NICE as a ‘routine’ treatment for advanced bladder cancer, but the drugmaker has been asked to submit a proposal for the immunotherapy’s inclusion within the Cancer Drugs Fund for a certain patient population.

More: NICE invites Roche to submit Tecentriq for CDF
Source: News